| Literature DB >> 27930300 |
Amit D Gujar1, Son Le2, Diane D Mao1, David Y A Dadey3,4, Alice Turski1, Yo Sasaki5, Diane Aum1, Jingqin Luo6,7, Sonika Dahiya8, Liya Yuan1, Keith M Rich1,7, Jeffrey Milbrandt5,9, Dennis E Hallahan3,7,9,10, Hiroko Yano1,5,7,9,11, David D Tran2, Albert H Kim12,7,9,11,13.
Abstract
Accumulating evidence suggests cancer cells exhibit a dependency on metabolic pathways regulated by nicotinamide adenine dinucleotide (NAD+). Nevertheless, how the regulation of this metabolic cofactor interfaces with signal transduction networks remains poorly understood in glioblastoma. Here, we report nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting step in NAD+ synthesis, is highly expressed in glioblastoma tumors and patient-derived glioblastoma stem-like cells (GSCs). High NAMPT expression in tumors correlates with decreased patient survival. Pharmacological and genetic inhibition of NAMPT decreased NAD+ levels and GSC self-renewal capacity, and NAMPT knockdown inhibited the in vivo tumorigenicity of GSCs. Regulatory network analysis of RNA sequencing data using GSCs treated with NAMPT inhibitor identified transcription factor E2F2 as the center of a transcriptional hub in the NAD+-dependent network. Accordingly, we demonstrate E2F2 is required for GSC self-renewal. Downstream, E2F2 drives the transcription of members of the inhibitor of differentiation (ID) helix-loop-helix gene family. Finally, we find NAMPT mediates GSC radiation resistance. The identification of a NAMPT-E2F2-ID axis establishes a link between NAD+ metabolism and a self-renewal transcriptional program in glioblastoma, with therapeutic implications for this formidable cancer.Entities:
Keywords: NAD+; NAMPT; glioblastoma; radiation resistance; self-renewal
Mesh:
Substances:
Year: 2016 PMID: 27930300 PMCID: PMC5187672 DOI: 10.1073/pnas.1610921114
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205